Author/Editor		Golob-Gulič, Tatjana
Title		Farmakoekonomika klopidogrela
Translated title		Pharmacoeconomic aspect of clopidogrel
Type		članek
Source		In: Hojs R, Krajnc I, Pahor A, et al, editors. Zbornik predavanj in praktikum 15. srečanje internistov in zdravnikov splošne medicine Iz prakse za prakso z mednarodno udeležbo; 2004 maj 7-8; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year		2004
Volume		str. 267-70
Language		slo
Abstract		Clopidogrel is an antiplatelet agent, which is more effective than acetylsalicylic acid (ASA) in the reduction of the combined risk of myocardial infarction (MI), ischemic stroke or vascular death. It is also effective in preventing recurrent MI, stroke or vascular death in patients presenting with acute coronary syndrome (ACS) without ST elevation in combination with standard antiplatelet therapy, which is ASA. Based on the CAPRIE and CURE trials and pharmacoeconomic analysis, treatment with clopidogrel is also cost-effective, meaning that the costs of additional treatment are acceptable as compared to the costs resulting from the illness itself and its economic burden.
Descriptors		PLATELET AGGREGATION INHIBITORS DRUG COSTS